多发性骨髓瘤的治疗进展

doi:10.12092/j.issn.1009-2501.2020.01.016

摘要/Abstract

摘要： 多发性骨髓瘤是发生于浆细胞的恶性肿瘤。骨髓中克隆性浆细胞异常增生，并分泌单克隆免疫球蛋白或其片段（M蛋白），导致相关器官或组织损伤。目前随着新药的研发、细胞免疫治疗的开展以及造血干细胞移植技术的提升，多发性骨髓瘤缓解深度和生存期明显延长。本文就近年来多发性骨髓瘤治疗的最新进展进行综述。

关键词: 多发性骨髓瘤, 蛋白酶体抑制剂, 免疫调节剂, 免疫治疗, 造血干细胞移植

Abstract: Multiple myeloma is a malignant tumor that occurs in plasma cells. Clonal plasma cells in bone marrow proliferate abnormally and secrete monoclonal immunoglobulin or its fragment (M protein), resulting in damage to related organs or tissues. At present, with the development of new drugs, the development of cellular immunotherapy and the improvement of hematopoietic stem cell transplantation technology, the depth of remission and survival of multiple myeloma are significantly prolonged. This article reviews the latest advances in the treatment of multiple myeloma in recent years.

Key words: multiple myeloma, proteasome inhibitor, immunomodulator, immunotherapy, hematopoietic stem cell transplantation

中图分类号:

R551.3

常香香，韦中玲，郑幸媛，李慧敏，黄来全. 多发性骨髓瘤的治疗进展[J]. 中国临床药理学与治疗学, 2020, 25(1): 107-116.

CHANG Xiangxiang, WEI Zhongling, ZHENG Xingyuan, LI Huimin, HUANG Laiquan. Progress in the treatment of multiple myeloma[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(1): 107-116.

参考文献

［1］Torimoto Y, Shindo M, Ikuta K, et al. Current therapeutic strategies for multiple myeloma ［J］. Int J Clin Oncol, 2015, 20(3): 423-430.
［2］黄月华, 潘崚. 硼替佐米的作用机制、临床应用及其疗效研究进展［J］. 实用诊断与治疗杂志, 2008, 22(4): 280-282.
［3］Chakraborty R, Muchtar E, Kumar S, et al. The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents［J］. Bone Marrow Transplant, 2017, 52(1): 34-40.
［4］Lakshman A, Singh PP, Rajkumar SV, et al. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma［J］. Am J Hematol, 2018, 93(2): 179-186.
［5］Gao M, Yang G, Han Y, et al. Single-agent bortezomib or bortezomib-based regimens as consolidation therapy after autologous hematopoietic stem cell transplantation in multiple myeloma: a meta-analysis of randomized controlled trials［J］. Int J Clin Exp Med, 2015, 8(8): 12202-12210.
［6］Spencer A, Lentzsch S, Weisel K, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR［J］. Haematologica, 2018, 103(12): 2079-2087.
［7］Zanwar S, Abeykoon JP, Kapoor P. Ixazomib: a novel drug for multiple myeloma［J］. Expert Rev Hematol, 2018, 11(10): 761-771.
［8］Gupta N, Hanley MJ, Xia C, et al. Clinical pharmacology of ixazomib: The first oral proteasome inhibitor ［J］. Clin Pharmacokinet, 2019, 58(4): 431-449.
［9］Hou J, Jin J, Xu Y, et al. Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study［J］. J Hematol Oncol, 2017, 10(1): 137.
［10］Kumar SK, Berdeja JG, Niesvizky R, et al. Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2 study［J］. Lancet Oncol, 2014, 15(13): 1503-1512.
［11］Gupta N, Diderichsen PM, Hanley MJ, et al. Population pharmacokinetic analysis of ixazomib, an oral proteasome inhibitor, including data from the phase III TOURMALINE-MM1 study to inform labelling ［J］. Clin Pharmacokinet, 2017, 56(11): 1355-1368.
［12］Touzeau C, Moreau P. Ixazomib in the management of relapsed multiple myeloma［J］. Future Oncol, 2018, 14(20): 2013-2020.
［13］Spencer A, Harrison S, Zonder J, et al. A phase 1 clinical trial evaluating marizomib, pomalidomide and low-dose dexamethasone in relapsed and refractory multiple myeloma (NPI-0052-107): final study results［J］. Br J Haematol, 2018, 180(1): 41-51.
［14］Di K, Lloyd GK, Abraham V, et al. Marizomib activity as a single agent in malignant gliomas: ability to cross the blood-brain barrier［J］. Neuro Oncol, 2016, 18(6): 840-848.
［15］Badros A, Singh Z, Dhakal B, et al. Marizomib for central nervous system-multiple myeloma［J］. Br J Haematol, 2017, 177(2): 221-225.
［16］Zhu YX, Kortuem KM, Stewart AK. Molecular mechanism of action of immune-modulatory drugs thalidomide, lenalidomide and pomalidomide in multiple myeloma［J］. Leuk Lymphoma, 2013, 54(4): 683-687.
［17］Soyer N, Patir P, Uysal A, et al. Efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma: a real-life experience［J］. Turk J Med Sci, 2018, 48(4): 777-785.
［18］Fuchida SI, Sunami K, Matsumoto M, et al. A phase II study of lenalidomide consolidation and maintenance therapy after autologous PBSCT in patients with multiple myeloma［J］. Int J Hematol, 2019, 109(1): 131. doi: 10.1007/s12185-018- 2557-5.
［19］Wang X, Walter M, Urak R, et al. Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma［J］. Clin Cancer Res, 2018, 24(1): 106-119.
［20］Kneppers E, van der Holt B, Kersten MJ, et al. Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial［J］. Blood, 2011, 118(9): 2413-2419.
［21］Mikhael J,Manola J,Dueck AC,et al.Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function:PrE1003, a PrECOG study［J］.Blood Cancer J,2018,8(9): 86.
［22］Endo S, Amano M, Nishimura N, et al. Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells［J］. Biochem Biophys Res Commun, 2016, 469(2): 236-242.
［23］Miguel JS, Weisel K, Moreau P, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial［J］. Lancet Oncol, 2013, 14(11): 1055-1066.
［24］Charlinski G, Grzasko N, Jurczyszyn A, et al. The efficacy and safety of pomalidomide in relapsed/refractory multiple myeloma in a "real-world" study: Polish Myeloma Group experience［J］. Eur J Haematol, 2018, 101(3): 354-361.
［25］Leleu X, Karlin L, Macro M, et al. Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial results［J］. Blood, 2015, 125(9): 1411-1417.
［26］Guedan S, Calderon H, Posey A J, et al. Engineering and design of chimeric antigen receptors［J］. Mol Ther Methods Clin Dev, 2019,12: 145-156.
［27］Garfall AL, Stadtmauer EA, Hwang W, et al. Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.［J］. JCI Insight, 2018, 3(8): e120505.
［28］Guo B, Chen M, Han Q, et al. CD138- directed adoptive immunotherapy of chimeric antigen receptor（CAR）-modified T cells for multiple myeloma［J］. J Cell Immunother, 2015, 2(1): 28-35.
［29］Ali SA, Shi V, Maric I, et al. T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma［J］. Blood, 2016, 128(13): 1688-1700.
［30］Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis relapsed multiple myeloma ［J］. J Clin Oncol, 2018, 36(22): 2267-2280.
［31］Chen KH, Wada M, Pinz KG, et al. A compound chimeric antigen receptor strategy for targeting multiple myeloma［J］. Leukemia, 2018, 32(2): 402-412.
［32］Lee L, Draper B, Chaplin N, et al. An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma［J］. Blood, 2018, 131(7): 746-758.
［33］Maus MV, June CH. Zoom Zoom: racing CARs for multiple myeloma［J］. Clin Cancer Res, 2013, 19(8): 1917-1919.
［34］Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma［J］. N Engl J Med, 2016, 375(8): 754-766.
［35］Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma［J］. N Engl J Med, 2016, 375(14): 1319-1331.
［36］Mateos MV, Dimopoulos MA, Cavo M, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma［J］. N Engl J Med, 2018, 378(6): 518-528.
［37］Dimopoulos MA, Sonneveld P, Leung N, et al. International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment［J］. J Clin Oncol, 2016, 34(13): 1544-1557.
［38］Rocchi S, Tacchetti P, Pantani L, et al. Safety and efficacy of daratumumab in dialysis-dependent renal failure secondary to multiple myeloma［J］. Haematologica, 2018, 103(6): e277-e278.
［39］Liu YC, Szmania S, van Rhee F. Profile of elotuzumab and its potential in the treatment of multiple myeloma［J］. Blood Lymphat Cancer, 2014, 2014(4): 15-27.
［40］Lonial S, Kaufman J, Laubach J, et al. Elotuzumab: a novel anti-CS1 monoclonal antibody for the treatment of multiple myeloma［J］. Expert Opin Biol Ther, 2013, 13(12): 1731-1740.
［41］Lamb YN. Elotuzumab: a review in relapsed and/or refractory multiple myeloma ［J］. Drugs, 2018, 78(14): 1481-1488.
［42］Lonial S, Dimopoulos M, Palumbo A, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma［J］. N Engl J Med, 2015, 373(7): 621-631.
［43］Dimopoulos MA, Lonial S, Betts KA, et al. Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 4-year follow-up and analysis of relative progression-free survival from the randomized ELOQUENT-2 trial［J］. Cancer, 2018, 124(20): 4032-4043.
［44］Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity and immune correlates of anti-PD-1 antibody in cancer［J］. N EngI J Med, 2012, 366(26): 2443-2454.
［45］Jing W, Gershan JA, Weber J, et al. Combined immune checkpoint protein blockade and low dose whole body irradiation as immunotherapy for myeloma［J］. J Immunother Cancer, 2015, 3(1):2.
［46］Badros A, Hyjek E, Ma N, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma［J］. Blood, 2017, 130(10): 1189-1197.
［47］Chan WK, Kang S, Youssef Y, et al. A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma［J］. Cancer Immunol Res, 2018, 6(7): 776-787.
［48］Seckinger A, Delgado JA, Moser S, et al. Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment ［J］. Cancer Cell, 2017, 31(3): 396-410.
［49］Zou J, Chen D, Zong Y, et al. Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma［J］. Cancer Sci, 2015, 106(5): 512-521.
［50］Krishnan A, Pasquini MC, Logan B, et al. Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial［J］. Lancet Oncol, 2011, 12(13): 1195-1203.
［51］Htut M, D'Souza A, Krishnan A, et al. Autologous/allogeneic hematopoietic cell transplantation versus tandem autologous transplantation for multiple myeloma: comparison of long-term postrelapse survival［J］. Biol Blood Marrow Transplant, 2018, 24(3): 478-485.
［52］张彤彤, 孙爱宁, 陈苏宁, 等. 381例血液病患者造血干细胞移植术后相关感染的临床分析［J］. 中华血液学杂志, 2014, 35(9): 857-859.
［53］Tamaki M, Nakasone H, Gomyo A, et al. Lower glomerular filtration rate predicts increased hepatic and mucosal toxicity in myeloma patients treated with high-dose melphalan［J］. Int J Hematol, 2018, 108(4): 423-431.
［54］Qazilbash HM, Bashir QM. 399 A randomized phase III trial of busulfan + melphalan VS melphalan alone for multiple myeloma［J］. 2017.
［55］Lahuerta JJ, Mateos MV, Martinez-Lopez J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival ［J］. J Clin Oncol, 2008, 26(35): 5775-5782.
［56］Aggarwal M, Agrawal N, Yadav N, et al. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma［J］. Ann Hematol, 2018, 97(10): 1869-1877.
［57］Stewart AK, Trudel S, Bahlis NJ, et al. A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 Trial［J］. Blood, 2013, 121(9): 1517-1523.
［58］Bergsagel PL, Mateos MV, Gutierrez NC, et al. Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma［J］. Blood, 2013, 121(6): 884-892.

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[3]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[4]	朱瑞芳, 郭东凯, 智慧, 江翊国, 张悦翎, 钱晓萍, 季士亮. ROS-NF-κB-p38MAPK通路探索榄香烯联合硼替佐米抗多发性骨髓瘤的机制研究[J]. 中国临床药理学与治疗学, 2023, 28(11): 1219-1226.
[5]	王甜甜, 曹俊杰, 刘旭辉, 裴仁治, 陆滢. 氟达拉滨联合后置环磷酰胺用于单倍体造血干细胞移植临床疗效分析[J]. 中国临床药理学与治疗学, 2022, 27(3): 295-301.
[6]	段圆圆, 李子坚. Ciltacabtagene autoleucel——治疗复发难治性多发性骨髓瘤的靶向BCMA CAR-T细胞新型疗法[J]. 中国临床药理学与治疗学, 2022, 27(10): 1145-1154.
[7]	李玮, 胡佳丽, 王凯, 贺毅憬. 黑色素瘤免疫治疗的研究现状与展望[J]. 中国临床药理学与治疗学, 2021, 26(9): 1053-1064.
[8]	鲍静, 陈晓文, 夏亮, 赵雨辰, 夏瑞祥, 夏海龙. 伊沙佐米治疗多发性骨髓瘤的临床疗效和安全性分析[J]. 中国临床药理学与治疗学, 2021, 26(7): 782-786.
[9]	彭敏, 黄攀豪, 邓银华, 刘文, 李威, 于珍, 夏青, 谢悦良. 造血干细胞移植患者伏立康唑稳态谷浓度监测及其影响因素分析[J]. 中国临床药理学与治疗学, 2021, 26(6): 640-646.
[10]	赵全铭，杨洋. 晚期三阴性乳腺癌的药物治疗进展[J]. 中国临床药理学与治疗学, 2020, 25(4): 475-480.
[11]	张锴婷，陈乃涵. 生物药在肿瘤治疗领域的临床研究进展[J]. 中国临床药理学与治疗学, 2020, 25(1): 32-43.
[12]	蒙秋华，田婧，覃斐章，覃杨，董敏. PD-1/PD-L1通路抑制剂在消化系统肿瘤免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2018, 23(8): 942-948.
[13]	封媛媛，丁凯阳，王翠翠. 大剂量化疗联合自体造血干细胞移植治疗淋巴瘤的临床疗效观察[J]. 中国临床药理学与治疗学, 2018, 23(12): 1397-1401.
[14]	章晓英，王康，邬莎，郭鹏. 低剂量奥氮平控制抗NMDAR脑炎精神症状的联系分析[J]. 中国临床药理学与治疗学, 2018, 23(11): 1292-1296.
[15]	吴海兵，张刚，韩彬，郭晓珺，吉兆宁. 多发性骨髓瘤患者住院化疗感染的临床特征及影响因素研究[J]. 中国临床药理学与治疗学, 2018, 23(1): 93-98.